Participant flow

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients · Source last updated 2020-12-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Ibrutinib (trademark name is IMBRUVICA®). 560 mg dose taken PO daily for 12 cycles (28 days each). Ibrutinib: Ibrutinib is a type of drug called a "kinase inhibitor." Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing.

   id

   FG000

   title

   Ibrutinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      enrolled but not dosed

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      screen failure

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         9

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         6

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

Participants enrolled from May 2017 through June 2019

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice